185 related articles for article (PubMed ID: 37245189)
1. Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Navari RM; Nelson WW; Shoaib S; Singh R; Zhang W; Bailey WL
Adv Ther; 2023 Jul; 40(7):3217-3226. PubMed ID: 37245189
[TBL] [Abstract][Full Text] [Related]
2. Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy.
Nelson WW; Vaidya V; Scott JA; Wang B; Lambert H; Holmes B; Bailey WL
Future Oncol; 2023 Jan; 19(1):29-36. PubMed ID: 36622264
[TBL] [Abstract][Full Text] [Related]
3. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Park SH; Binder G; Corman S; Botteman M
J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
[No Abstract] [Full Text] [Related]
4. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
Botteman M; Nickel K; Corman S; Turini M; Binder G
Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
7. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.
Piechotta V; Adams A; Haque M; Scheckel B; Kreuzberger N; Monsef I; Jordan K; Kuhr K; Skoetz N
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012775. PubMed ID: 34784425
[TBL] [Abstract][Full Text] [Related]
8. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
Hatoum HT; Lin SJ; Buchner D; Cox D
Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
[TBL] [Abstract][Full Text] [Related]
9. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
Hesketh PJ; Palmas M; Nicolas P
Support Care Cancer; 2018 Apr; 26(4):1151-1159. PubMed ID: 29080920
[TBL] [Abstract][Full Text] [Related]
10. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial.
Tsuji D; Suzuki K; Kawasaki Y; Goto K; Matsui R; Seki N; Hashimoto H; Hama T; Yamanaka T; Yamamoto N; Itoh K
Support Care Cancer; 2019 Mar; 27(3):1139-1147. PubMed ID: 30094732
[TBL] [Abstract][Full Text] [Related]
11. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
[TBL] [Abstract][Full Text] [Related]
13. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
15. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
16. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
[TBL] [Abstract][Full Text] [Related]
17. Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
Navari RM; Binder G; Bonizzoni E; Clark-Snow R; Olivari S; Roeland EJ
Future Oncol; 2021 Aug; 17(23):3027-3035. PubMed ID: 33878896
[TBL] [Abstract][Full Text] [Related]
18. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting.
Burke TA; Wisniewski T; Ernst FR
Support Care Cancer; 2011 Jan; 19(1):131-40. PubMed ID: 20101417
[TBL] [Abstract][Full Text] [Related]
19. Comparison of healthcare resource use between patients receiving ondansetron or palonosetron as prophylaxis for chemotherapy-induced nausea and vomiting.
Yeh YC; McDonnell A; Klinger E; Fowler B; Matta L; Voit D; Reddy P
J Oncol Pharm Pract; 2011 Sep; 17(3):179-85. PubMed ID: 20452991
[TBL] [Abstract][Full Text] [Related]
20. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
